DENVER, Oct. 7, 2025 /PRNewswire/ — QuantiPath (quantipath.bio), the biotechnology company advancing genomic pathogen diagnostics for food safety, today announced the appointment of Jeff Nauseda as Director of Market Development, with principal responsibility for scaling QuantiPath’s presence in the beef and pet food sectors. This strategic hire strengthens a leadership team that already offers deep coverage in poultry and swine.
With more than 22 years of experience in strategic business development and food safety markets, Jeff brings a proven track record in building commercial partnerships, aligning technical solutions to customer needs, and navigating highly regulated industries. His background includes tenures at SGS, bioMérieux and Abbott Laboratories.
In his new role, Jeff Nauseda will lead efforts to expand into beef and pet food markets — two high-growth segments where highly precise and accurate pathogen testing is becoming increasingly critical. He will collaborate with QuantiPath’s technical, regulatory, and sales teams to tailor the upcoming GenoPATHX platform to the specific pathogen, regulatory, and operational needs of beef and pet food producers and processing labs. LinkedIn
“Bringing Jeff into the fold at this pivotal time is a meaningful step forward for QuantiPath,” said John LoPorto, President & CEO. “His domain expertise in commercializing rapid methods for foodborne pathogen detection, combined with his strategic relationships, will accelerate our entry into the beef and pet food markets. We now have strong leadership across poultry, swine, and now beef and pet — enabling us to offer a complete livestock- and protein-industry diagnostic suite.”
QuantiPath’s flagship product, GenoPATHX, is a deep-serotyping qPCR assay capable of identifying and quantifying multiple Salmonella serovars in a single test with no need for sample enrichment. The platform is designed to deliver same-shift actionable results, giving food processors, and labs timely visibility and insight into product and environmental contamination. The GenoPATHX offerings for STEC (Shiga toxin–producing E. coli), Listeria and Campylobacter will see a staggered release in 2026.
QuantiPath recently rebranded from Food Supply Security to better reflect its mission of pathogen quantification and diagnostic precision. The company has already built strong domain coverage: leadership includes a vice president dedicated to poultry, two directors aligned with livestock sectors, and science and operations expertise ready to support cross-species deployment.
Nauseda’s addition reinforces QuantiPath’s market readiness as GenoPATHX is readied for full commercial rollout, anchoring its strategic path into new verticals where genomic diagnostic demand is on the rise.
About QuantiPath
QuantiPath is a biotechnology company revolutionizing food safety testing through precision genetic diagnostics. Its flagship product, GenoPATHx, is the only rapid test kit that identifies and quantifies multiple Salmonella serovars simultaneously, offering the food industry unparalleled visibility into microbial contamination. Backed by a team of geneticists, software engineers, and industry veterans, QuantiPath’s mission is to deliver data clarity, consumer safety, and operational confidence from farm to fork. Learn more at www.QuantiPath.bio.
SOURCE QuantiPath
Telehealth Provider Offers FDA-Approved and Compounded Weight Loss Medications in All 50 States, Subject to…
Telehealth Platform Facilitates Compounded Semaglutide and Tirzepatide Access Through Licensed Provider Evaluation as FDA Shortage…
Analysis examines best peptides for boosting growth hormone as ReadyRx lists prescription sermorelin in injectable…
Discover the best fat burner for men in 2025. Explore Wolfson Brand’s effective fat-burning supplements…
Industry Analysis Examines How Cost, Safety, and Access Considerations Shape Semaglutide Choices as MEDVi Lists…
Deploying “Proof of Human” Infrastructure throughout Japan, a Technology Envisioned by Sam Altman and Alex…